SG10201408158SA - Composition and methods used during anti-hiv treatment - Google Patents
Composition and methods used during anti-hiv treatmentInfo
- Publication number
- SG10201408158SA SG10201408158SA SG10201408158SA SG10201408158SA SG10201408158SA SG 10201408158S A SG10201408158S A SG 10201408158SA SG 10201408158S A SG10201408158S A SG 10201408158SA SG 10201408158S A SG10201408158S A SG 10201408158SA SG 10201408158S A SG10201408158S A SG 10201408158SA
- Authority
- SG
- Singapore
- Prior art keywords
- composition
- used during
- methods used
- during anti
- hiv treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1868808P | 2008-01-03 | 2008-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201408158SA true SG10201408158SA (en) | 2015-03-30 |
Family
ID=41091283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013000195A SG187420A1 (en) | 2008-01-03 | 2008-12-31 | Composition and methods used during anti-hiv treatment |
| SG10201408158SA SG10201408158SA (en) | 2008-01-03 | 2008-12-31 | Composition and methods used during anti-hiv treatment |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013000195A SG187420A1 (en) | 2008-01-03 | 2008-12-31 | Composition and methods used during anti-hiv treatment |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20110046091A1 (en) |
| EP (1) | EP2234620B1 (en) |
| JP (2) | JP5570999B2 (en) |
| CN (3) | CN102698276B (en) |
| AU (1) | AU2008353145B2 (en) |
| BR (1) | BRPI0821962A2 (en) |
| CA (1) | CA2711569C (en) |
| DK (1) | DK2234620T3 (en) |
| ES (1) | ES2573641T3 (en) |
| PL (1) | PL2234620T3 (en) |
| PT (1) | PT2234620E (en) |
| SG (2) | SG187420A1 (en) |
| WO (1) | WO2009115652A2 (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013251237B2 (en) * | 2008-01-03 | 2016-03-17 | Universite D' Aix-Marseille | Bitherapy and tritherapy used for treating an HIV-positive patient |
| FR2926020B1 (en) * | 2008-01-03 | 2010-08-13 | Univ Aix Marseille Ii | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION |
| US20130116171A1 (en) | 2010-04-16 | 2013-05-09 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf |
| RS60631B1 (en) | 2014-11-21 | 2020-09-30 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| TWI708786B (en) | 2014-12-23 | 2020-11-01 | 美商必治妥美雅史谷比公司 | Antibodies to tigit |
| BR112017020952A2 (en) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | cancer treatment method, composition and use of composition |
| AU2016285920A1 (en) | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
| AU2016344134A1 (en) | 2015-10-30 | 2018-05-31 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs |
| AU2016356780A1 (en) | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| KR20180094036A (en) | 2015-12-15 | 2018-08-22 | 브리스톨-마이어스 스큅 컴퍼니 | CXCR4 receptor antagonist |
| EP3414347A4 (en) * | 2016-02-11 | 2019-10-09 | Qiagen Sciences, LLC | Additive to improve sequencing by synthesis performance |
| MA44723A (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics Inc | HUMAN CD40 BINDING AGONIST ANTIBODIES AND THEIR USES |
| WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
| WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| JP7358361B2 (en) | 2018-01-12 | 2023-10-10 | ブリストル－マイヤーズ スクイブ カンパニー | Antibodies against TIM3 and their uses |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| PE20211604A1 (en) | 2018-07-09 | 2021-08-23 | Five Prime Therapeutics Inc | ILT4 UNION ANTIBODIES |
| CA3133155A1 (en) | 2019-03-19 | 2020-09-24 | Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron | Combination therapy for the treatment for cancer |
| JP2022528887A (en) | 2019-04-02 | 2022-06-16 | バイスクルテクス・リミテッド | Bicycle toxin conjugates and their use |
| US20230242478A1 (en) | 2019-05-13 | 2023-08-03 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
| AR119821A1 (en) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS |
| CA3149719A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| KR20220103753A (en) | 2019-11-19 | 2022-07-22 | 브리스톨-마이어스 스큅 컴퍼니 | Compounds useful as inhibitors of helios proteins |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| WO2023122777A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2024028363A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| WO2024028365A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
| WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| WO2024033388A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| WO2024033458A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5652227A (en) | 1995-01-30 | 1997-07-29 | Teronen; Olli Pekka | Inhibition of the degradation of connective tissue matrix protein components in mammals |
| EP0738510A3 (en) | 1995-04-20 | 2005-12-21 | L'oreal | Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties. |
| US5902805A (en) | 1996-04-22 | 1999-05-11 | L'oreal | Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same |
| US20030105121A1 (en) * | 1999-07-27 | 2003-06-05 | Bernard Bihari | Method of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents |
| JP2001253827A (en) * | 2000-02-15 | 2001-09-18 | Pfizer Prod Inc | Composition and method for treating osteoporosis |
| US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| EP1311266A2 (en) * | 2000-06-28 | 2003-05-21 | SuperGen, Inc. | Combination hiv therapy including camptothecin |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078531A1 (en) * | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| GB0220885D0 (en) * | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
| ES2209658B1 (en) * | 2002-12-05 | 2005-10-01 | Proyecto Empresarial Brudy, S.L. | USE OF DOCOSAHEXAENOIC ACID AS AN ACTIVE PRINCIPLE FOR THE TREATMENT OF LIPODYSTROPHY. |
| AU2003295940A1 (en) * | 2002-12-16 | 2004-07-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Treatment of hiv infection through combined administration of tipranavir and capravirine |
| CA2552404A1 (en) * | 2004-01-29 | 2005-08-18 | Applied Research Systems Ars Holding N.V. | Methods and compositions for the treatment of lipodystrophy |
| KR20050083536A (en) | 2004-02-23 | 2005-08-26 | (주)티젠바이오텍 | The use of bisphosphonates for stimulating of collagen synthesis |
| WO2007109585A2 (en) * | 2006-03-17 | 2007-09-27 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
| JP2006188445A (en) * | 2005-01-05 | 2006-07-20 | Ono Pharmaceut Co Ltd | Nitrogen-containing heterocyclic compound and pharmaceutical use thereof |
| FR2903312B1 (en) * | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | USE OF INHIBITORS OF HMG-COA REDUCTASE AND FARNESYL-PYROPHOSPHATE SYNTHASE IN THE PREPARATION OF A MEDICINAL PRODUCT |
| FR2926020B1 (en) * | 2008-01-03 | 2010-08-13 | Univ Aix Marseille Ii | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION |
-
2008
- 2008-12-31 SG SG2013000195A patent/SG187420A1/en unknown
- 2008-12-31 SG SG10201408158SA patent/SG10201408158SA/en unknown
- 2008-12-31 AU AU2008353145A patent/AU2008353145B2/en not_active Ceased
- 2008-12-31 DK DK08873368.8T patent/DK2234620T3/en active
- 2008-12-31 CN CN201210104076.XA patent/CN102698276B/en not_active Expired - Fee Related
- 2008-12-31 PL PL08873368.8T patent/PL2234620T3/en unknown
- 2008-12-31 JP JP2010541090A patent/JP5570999B2/en not_active Expired - Fee Related
- 2008-12-31 CN CN200880127741.9A patent/CN101990432B/en not_active Expired - Fee Related
- 2008-12-31 EP EP08873368.8A patent/EP2234620B1/en not_active Not-in-force
- 2008-12-31 PT PT08873368T patent/PT2234620E/en unknown
- 2008-12-31 US US12/811,474 patent/US20110046091A1/en not_active Abandoned
- 2008-12-31 CA CA2711569A patent/CA2711569C/en not_active Expired - Fee Related
- 2008-12-31 WO PCT/FR2008/001844 patent/WO2009115652A2/en active Application Filing
- 2008-12-31 CN CN201310236171.XA patent/CN103372215B/en not_active Expired - Fee Related
- 2008-12-31 BR BRPI0821962A patent/BRPI0821962A2/en not_active Application Discontinuation
- 2008-12-31 ES ES08873368.8T patent/ES2573641T3/en active Active
-
2011
- 2011-12-14 JP JP2011272922A patent/JP5622713B2/en not_active Expired - Fee Related
-
2015
- 2015-06-08 US US14/733,725 patent/US9545412B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL2234620T3 (en) | 2016-09-30 |
| CN103372215B (en) | 2016-03-09 |
| ES2573641T3 (en) | 2016-06-09 |
| AU2008353145B2 (en) | 2013-09-12 |
| JP2012062322A (en) | 2012-03-29 |
| JP5570999B2 (en) | 2014-08-13 |
| CN103372215A (en) | 2013-10-30 |
| SG187420A1 (en) | 2013-02-28 |
| WO2009115652A2 (en) | 2009-09-24 |
| CN101990432B (en) | 2016-01-20 |
| BRPI0821962A2 (en) | 2019-05-07 |
| US9545412B2 (en) | 2017-01-17 |
| US20150342970A1 (en) | 2015-12-03 |
| CA2711569C (en) | 2017-08-01 |
| US20110046091A1 (en) | 2011-02-24 |
| EP2234620B1 (en) | 2016-03-09 |
| JP5622713B2 (en) | 2014-11-12 |
| PT2234620E (en) | 2016-06-20 |
| JP2011508764A (en) | 2011-03-17 |
| AU2008353145A1 (en) | 2009-09-24 |
| EP2234620A2 (en) | 2010-10-06 |
| CA2711569A1 (en) | 2009-09-24 |
| CN102698276A (en) | 2012-10-03 |
| CN101990432A (en) | 2011-03-23 |
| DK2234620T3 (en) | 2016-06-06 |
| WO2009115652A3 (en) | 2010-01-21 |
| CN102698276B (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201408158SA (en) | Composition and methods used during anti-hiv treatment | |
| EP2361089A4 (en) | Compositions and methods for the treatment of altered -synuclein function | |
| EP2314278A4 (en) | Hair treatment composition | |
| IL202015A0 (en) | Methods and compositions for treating skin conditions | |
| EP2212440A4 (en) | Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas | |
| EP2317931A4 (en) | Tissue modification devices and methods of using the same | |
| IL210810A0 (en) | Compositions for the treatment of pain and/or inflamtion | |
| ZA201006293B (en) | Composition and method for seed treatment use | |
| HK1159498A1 (en) | Methods and compositions for the treatment of cancer | |
| EP2331123A4 (en) | Compositions and methods for the treatment of hepatitis c | |
| IL210097A0 (en) | Compositions and methods for treating unfluenza | |
| GB0718446D0 (en) | Compositions and methods for the treatment of infection | |
| EP2429584A4 (en) | Methods and compositions for treatment | |
| EP2340027A4 (en) | Methods and compositions for the treatment of cancer | |
| EP2340297A4 (en) | Composition, method of making the same, and use thereof | |
| EP2249789A4 (en) | Compositions and methods for the treatment of xerostomia | |
| EP2209458A4 (en) | Skin treatment compositions | |
| EP2249823A4 (en) | Octanoic acid formulations and methods of treatment using the same | |
| HK1193379A1 (en) | Remedial composition and treatment methods | |
| EP2293670A4 (en) | Compositions and methods for nail fungus treatment | |
| GB0823497D0 (en) | Immunogenic composition and use thereof | |
| EP2285398A4 (en) | Methods and compositions for the treatment of obesity | |
| IL209947A0 (en) | Compositions and methods for treating corneal inflammation | |
| EP2512504A4 (en) | Treatment composition and method | |
| GB0714500D0 (en) | composition and treatment |